Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Patients were randomly assigned to six cycles of docetaxel 100 mg/m2 every 3 weeks, with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 23; no. 19; pp. 4265 - 4274
Main Authors: MARTY, Michel, COGNETTI, Francesco, KENNEDY, John, O'BYRNE, Kenneth, CONTE, Pier Franco, GREEN, Michael, WARD, Carol, MAYNE, Karen, EXTRA, Jean-Marc, MARANINCHI, Dominique, SNYDER, Ray, MAURIAC, Louis, TUBIANA-HULIN, Michèle, CHAN, Stephen, GRIMES, David, ANTON, Antonio, LLUCH, Ana
Format: Journal Article
Language:English
Published: Baltimore, MD American Society of Clinical Oncology 01-07-2005
Lippincott Williams & Wilkins
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first